Preservation of platelet integrity and responsiveness was examined in platelet concentrates prepared in the presence of various formulations and combinations of plateletactivation inhibitors affecting intracellular levels of cyclic 3-5' adenosine monophosphate (CAMP). Platelet concentrates were prepared and stored in an artificial medium for two weeks at 22'C. Markers of metabolic activity (pH, lactate, p02, pCOz in the medium), aggregation response, hypotonic shock response, and glycoprotein Ib (GPIb) expression were assessed along with direct measurements of cAMP in platelet pellets and thromboxane Bz (TxB,) in the supernate. The platelet concentrates prepared with only adenylate-cyclase stimulators (prostaglandin E -l or forskolin) showed less maintenance of the integrity and re-HEN ADENYLATE-CYCLASE stimulators such as prostaglandin E-l (PGE-1) or prostacyclin were first used to try to improve the preservation of platelets stored for transfusion, the results were only marginally positive.I4 Even more recent studies with contemporary storage containers and evaluation criteria showed no sustained beneficial effect of these agents5" Although a plausible interpretation of these findings is that platelet activation does not play a major role in the degeneration of platelets during storage, there is much evidence to the contrary.'"' Also, the previous studies did not directly assess evidence of platelet activation in the treated platelet concentrates, nor measure the effectiveness of action of these activation inhibitors on cyclic 3'-5' adenosine monophosphate (CAMP) levels. Others have shown that PGE-I and PGI-2 produce only a transient increase in cAMP in platelet preparations because of the rapid breakdown of cAMP by Thus, a likely explanation for the ineffectiveness of PGE-1 or PGI-2 in preservation of platelets over 3 to 5 days might be that cAMP levels were not increased sufficiently for an appropriate duration, so that platelet activation was not adequately inhibited for the entire storage period.
HEN ADENYLATE-CYCLASE stimulators such as prostaglandin E-l (PGE-1) or prostacyclin were first used to try to improve the preservation of platelets stored for transfusion, the results were only marginally positive.I4 Even more recent studies with contemporary storage containers and evaluation criteria showed no sustained beneficial effect of these agents5" Although a plausible interpretation of these findings is that platelet activation does not play a major role in the degeneration of platelets during storage, there is much evidence to the contrary.'"' Also, the previous studies did not directly assess evidence of platelet activation in the treated platelet concentrates, nor measure the effectiveness of action of these activation inhibitors on cyclic 3'-5' adenosine monophosphate (CAMP) levels. Others have shown that PGE-I and PGI-2 produce only a transient increase in cAMP in platelet preparations because of the rapid breakdown of cAMP by Thus, a likely explanation for the ineffectiveness of PGE-1 or PGI-2 in preservation of platelets over 3 to 5 days might be that cAMP levels were not increased sufficiently for an appropriate duration, so that platelet activation was not adequately inhibited for the entire storage period.
To investigate this hypothesis we tested the effectiveness of several CAMP-active agents and combinations in platelet concentrates that were stored in artificial media for up to 2 weeks to accentuate differences in treatment groups. By measuring cAMP levels in the stored platelets, and thromboxane B2 (TxB2) in the supernate, we were able to show that PGE-1 by itself failed to produce a sustained elevation of CAMP over the extended storage period and consequently failed to prevent platelet activation and its deleterious effects. Therefore, we tested other compounds including phosphodiesterase inhibitors as in previous ~t u d i e s . '~"~ Two different types of adenylate-cyclase stimulators were used (PGE-I or forskolin) along with three different phosphodiesterase inhibitors (theophylline, caffeine, isobutyl-methylxanthine [IBMX}). A minimal number of doses and combinations are presented here to illustrate the relationship between cAMP levels and status of the platelets during storage.
These studies provide further evidence that prevention of platelet activation is beneficial for long-term maintenance sponsiveness markers and greater loss of GPlb than concentrates prepared with phosphodiesterase inhibitors (theophylline or caffeine) or combinations with the above. These results were correlated with the ability of these compounds to sustain elevation of cAMP above'basal level during the entire extended-storage period. The strong correlation (r. = -0.67) between elevation of cAMP levels and suppression of TxBz production suggests that the phosphodiesterase inhibitors provided better protection than stimulators of adenylate cyclase alone thnough a reduction in platelet activation and its deleterious effects on preservation of platelets during storage. This is a US government work. There are no restrictions on its use.
of platelet integrity for transfusion. The compounds tested in this study are reversible in their effects on platelet function and so may prove to be useful in the clinical applications of our findings. The ultimate goal of this research is to show a feasible method for greatly extending the shelf life of platelet concentrates in the blood bank.
Sorvall RC-3C (DuPont, Wilmington, DE) at 3,100 rpm for 3 minutes, 5 seconds for a total-force integral of 1.5 X IO' rad2/s. Oneeighth volume citrated saline (7 parts 0.9% saline plus 1 part CPDA-1) plus or minus dissolved inhibitors was added through a samplingsite coupler to the platelet-rich plasma for a 30-minute incubation at room temperature before the second centrifugation (3,000 rpm, IO minutes) to pellet the platelets. Artificial medium containing the same inhibitors was added after aspiration of platelet-poor plasma, and the platelets were resuspended after 30 to 45 minutes. The volume of artificial medium to be added (40 to 60 mL) was based on a target platelet count in the concentrate of 1.35 X 109/mL.
After resuspension, the platelet concentrates were treated with 2.4 mL 8.4% NaHC03 per 60 mL ofconcentrate and stored in room air with slow (two rotations per minute) tumbling agitation at 22°C in PL-732 plastic containers folded to give a surface-to-volume ratio of 4 cm2/mL instead of the usual 7 cm2/mL. The decrease in bag surface area by itself makes very little difference in standard concentrates, but seems to accentuate the effects of added platelet-activation inhibitors as we have reported elsewhere."I6 Samples were withdrawn as needed through sampling-site couplers with sterile technique.
Test and assays. pH, p02, and pC02 were measured at 37°C on a Radiometer ABL Model 30 blood-gas analyzer (Radiometer, Copenhagen, Denmark). Because the samples were at 22°C before analysis, the measurements may be slightly altered from the actual values in the storage bag.
Platelet counts were determined on a Coulter Counter S Plus IV (Hialeah, FL).
Hypotonic shock response (HSR) was measured turbidimetrically as the rate of recovery after swelling of platelets in the presence of one-third volume deionized water as described e1se~here.l~ Aggregation response was measured on a BioData PAP-4 aggregometer (Hatboro, PA) with I X 1 0-5 mol/L adenosine diphosphate (ADP) (BioData) or 1.5 mg/mL ristocetin (Helena Labs, Beaumont, TX) (final concentrations) after pelleting and resuspension of platelet concentrate samples in inhibitor-free citrated plasma at a concentration of (M to 0.4 X 109/mL.
Released lactic dehydrogenase (LDH) was measured on a Technicon RA-1000 discrete analyzer (Tarrytown, NY) in the supernate The sample was further diluted 1: 10 in isotonic saline beforeanalysis on a Becton Dickinson FACS 440 flow cytometer (Mountain View, CA). Cursors were set on fluorescence histograms on the Data Consort 40 system to determine the percentage of platelets appearing to be negative for specific binding of AN-51 (GPIb-) and to determine the mean peak channel of the positive fluorescence distribution.
Intracellular cyclic AMP levels were determined from frozen platelet pellets with a commercial radioimmunoassay kit (Diagnostic Products, Los Angeles, CA) and reported in units of picomoles/ 109 platelets.
TxB2 levels were determined in the supernate of platelet-concentrate samples (Eppendorf Microfuge 15,600g for 2 minutes) with a commercial radioimmunoassay kit (New England Nuclear, Boston. MA) and reported in units of nanograms/109 platelets.
Inhibitor formulations. Several different CAMP-active agents were used singly or in combination in these studies; the final concentrations of these agents in the platelet concentrate were as follows: (1) .o 1
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The lowest (best) ranks were accorded to the formulations with the least change in pH and lowest lactate levels, lowest pOz in the bag, highest pC02, Abbreviation: NS. not significant.
Metabolic markers are pH, pot, pC02, and lactate.
t Aggregation studies are 10 prnol/L ADP and 1.5 mg/rnL ristocetin; %T and slope.
* Integrity markers are HSR, GPlb positivity, and LDH released.
highest aggregation slopes, greatest change in %T for each agonist, highest HSR, lowest released LDH, and lowest % GPlb-subpopulation.
count (less than 1 X 109/mL) or evidence of bacterial contamination. Assays of cAMP and TxB2 were performed on each unit, but not all of the other parameters were measured on each because of sampling-volume limitations. Statisficd methods. All statistical analyses were made with the SPSS/PC+ 4.0 statistical package. Because of the skewness in the numeric measures of the various cell markers used to evaluate the effectiveness of the CAMP-formulation groups, a rank transformation was used to convert the numeric measures to ranks. The lower ranks were assigned to those numeric values associated with the best marker performance, whereas the higher ranks were assigned to those numeric values associated with the poorest marker performance. Comparisons of metabolic activity, aggregation response, cell integrity, cAMP level, and TxB2 level between the various CAMPactive formulation groups was done by an analysis ofvariance ofthe ranks. Paiwise mean comparisons were analyzed with the Tukey multiple-range test. The Kendall coefficient of concordance was used to assess the extent to which the various cell markers agreed in 
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For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From generated from the forskolin-treated platelet formulation 3 are mentioned only briefly in the text because of the interference we experienced in obtaining a precise platelet CAMP level in these samples.
Metabolic markers. The platelet-concentrate storage medium used in these studies contains buffering compounds and nutrients in a balanced salt solution to provide support of platelet metabolic activity for 7 to 10 days." Extension of the storage period to 20 days served to accentuate the nonlinear changes and differences in pH, lactate, pol, and K O 2 among the treatment groups. As seen in Fig l , the pH was maintained best in the formulations containing a phosphodiesterase inhibitor. The platelet concentrates treated only with PGE-l showed a significant decrease in pH after the tenth day of storage similar to that in the control group. This finding was apparently caused by the increased production of lactate in the absence of a phosphodiesterase inhibitor. Continued respiratory activity was more evident in the platelet concentrates containing 2 mmol/L theophylline or caffeine as judged by lower pOz and higher pC02 inside the containers in the latter phases of the storage period. It seemed that PGE-I alone did not prevent or retard the metabolic changes that occurred after 10 to 15 days in the controls. Formulations 3 to 5 also showed severe metabolic changes. The pH decreased to less than 6.0 in each of the IBMX-treated platelet concentrates by day 15, and the lactate levels reached 40 to 50 mmol/L; the p 0 2 and pc02 values at day 15 indicated no further respiratory activity. The platelet concentrates containing forskolin were in a similar The rank transformations of the metabolic measures at days 10, 15, and 20 are given in Table l . It is seen that formulations 6 to 8 clearly surpassed the others at all days. The common feature of these formulations was the presence of a higher concentration (2 mmol/L) of an effective phosphodiesterase inhibitor (theophylline or caffeine). The significant concordance coefficients for days 10, 15, and 20 show that all four metabolic markers were in strong agreement in ranking the formulations.
Integrity und responsiveness markers. The response of platelets to hypotonic shock has been used extensively to assess the preservation of platelets in vitro in relation to their likely recoveries in vivo in autologous infusions.'' In our study, the hypotonic shock test showed better responsiveness in platelet concentrates prepared with the formulations containing a phosphodiesterase inhibitor (6 to 8) after 10 to 15 days of storage (Fig 2A) . Whether this finding predicts accurately an enhanced recovery or survival of these platelets after infusion is uncertain, but preliminary in vivo evidence presented elsewhere2' is encouraging in that platelet concentrates prepared in formulation 8 gave a much improved lifespan measurement over controls in autologous donors. Another general marker of cell integrity used in this study was the cumulative release of LDH into the supernate during storage. Again, the formulations containing a phosphodiesterase (6 to 8) inhibitor prevented a general rise in LDH better than PGE-l alone (Fig 2B) .
Aggregation and agglutination responses were tested after the stored platelets were resuspended in inhibitor-free citrated plasma. Typical light-transmittance tracings from four types of concentrates are depicted in Fig 3. At day 10, formulation 1 without inhibitors showed little responsiveness to either 10 pmol/L ADP or 1.5 mg/mL ristocetin; at day 15, the concentrates with PGE-l only (formulation 2) also showed significantly worse response than those formulations containing a phosphodiesterase inhibitor (formulations 7 and 8). For statistical comparisons among groups, the slope and maximum extent of aggregation for each sample tested were ranked and summarized in Table 1 .
We" and ~t h e r s~~* *~ have shown that GPIb expression is altered during storage of platelets; a population of platelets appears that no longer specifically binds MoAbs to surface GPIb (GPIb-). During extended storage (10 to 20 days), the specific binding of GPIb MoAbs decreases, in general, for the whole distribution of platelets, but may be moderated by the addition of PGE-1 and theophylline.'* In the present study, the concentrates without inhibitors (formulation l) showed a substantial population of GPIb-platelets at day 10 and a broad shift in immunofluorescence at day 15, also evident in the concentrate with PGE-l only (formulation 2) (see examples in Fig 4) . The concentrates containing phosphodiesterase inhibitors (formulations 7 and 8) showed very little change in the broad distribution pattern and only a minor appearance of apparently GPIb-platelets. The data means for GPIb-platelets among formulations 1, 2, 6, 7, and 8 are shown in Fig 5. These data for each formulation were ranked along with HSR and supernatant LDH levels as integrity markers for statistical comparisons shown in Table l .
As was observed in the metabolic markers, the IBMX or forskolin-treated concentrates showed variably poor results by day 15; no response in the hypotonic shock test, LDH levels between 2% to 49%, little or no aggregation with ADP or ristocetin, and 8% to 80% GPIb-platelets by flow cytometry. The units containing 500 pmol/L caffeine showed wide variability in results at day 15 and 20, but with better average values than IBMX or forskolin: 0% to 85% HSR, LDH levels between 6% to 19%, three of four units still aggregated fully with ADP or ristocetin, and only 12% to 59% platelets were GPIb-.
The rankings of these markers in Table 1 show a pattern mostly consistent with the above analysis of metabolic activity. The best rankings were achieved with formulation (6)
to (8) at days l5 and 20. Concordance among the aggregation or integrity markers was less than that for the metabolic markers, except at the later time points. For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From Overall rankings. Table 2 presents the means and standard deviations of the ranks assigned to the performance of the 11 parameters of function or integrity in seven of the formulations (excluding forskolin because of the lack of cAMP data) after 15 and 20 days of storage. Analysis of variance of these mean ranks showed that the group of "good" preservation formulations, groups 6 to 8, all had significantly lower mean ranks than the group of "poor" preservation formulations, groups I to 5, at both day 15 and 20 (P I .05). None of the "good" Eormulations were significantly different from each other by this analysis. However, the analysis of variance clearly shows that the formulations containing 2 mmol/L caffeine or theophylline, or a combination of PGE-l and theophylline were superior to the other formulations in platelet preservation during storage lasting through 20 days. Formulations 1 to 5 were clearly inferior, possibly because of the lack of an effective dose of a phosphodiesterase inhibitor.
Cyclic AMP and TxB2. To illuminate the mechanism whereby phosphodiesterase inhibitors appeared to work better than adenylate-cyclase stimulators in platelet preservation, CAMP levels were measured directly in platelet pellets obtained during the storage period from each of the formulations and compared with the levels of TxB2 in the su- pernate. As illustrated in Fig 6 , cAMP levels were highest in formulation 8 with both PGE-I and theophylline present. In formulations 6 and 7 containing only 2 mmol/L theophylline or caffeine, cAMP reached a high of only 50 pmol/ IO' platelets as a maximum in any one platelet concentrate, but stayed above the minimal levels seen in formulations 1 and 2 without a phosphodiesterase inhibitor. In data not shown, formulation 5 , with 500 pmol/L caffeine, gave a peak cAMP value of only 32 pmol/109 platelets, and mean values were not significantly different from 1 and 2. Formulation 4, with IBMX, showed even lower cAMP values than 5. AssaysofcAMP in formulation 3, with forskolin, were not linear with dilution, and thus were uninterpretable in our study. Because ofthis difficulty, forskolintreated concentrates were not included in the figures or overall statistical analysis of CAMP effects.
TxB2 was assayed in the supernate of samples from stored platelet concentrates as an index of platelet activation because many of the changes in platelet integrity and function during storage may be described as a consequence of activation." The effect of an adequate dose of a phosphodiesterase inhibitor was plainly evident in the cAMP/TxB2 correlation plots in Fig 7. By day 15 or 20, formulation 1 and 2 were clearly higher in TxB2 levels than formulations 6, 7, and 8. Only at day 20 did it appear that formulation 8, with the highest cAMP levels, had the lowest TxB2; however, this could be appreciated only on the logarithmic scale in Fig 7  and may not be relevant. Among the nonillustrated formulations, Forskolin ( 3 ) and IBMX (4) gave mean TxB2 levels at day 15 and day 20 2400 ng/ 1 O9 platelets; formulation 5. with 500 pmol/L caffeine, gave highly variable results with mean TxB2 = 60 at day I5 and 389 at day 20. Table 3 shows the results of transforming the numeric measures of cAMP and TxB2 to ranks. The formulations containing 2 mmol/L concentration of a phosphodiesterase inhibitor (formulations 6 to 8) had higher cAMP and lower TxB2 levels than the other formulations.
The Spearman rank correlations show a strong relationship between the rank orders of cAMP and TxBz levels at all storage times. 
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The correlations at 15 and 20 days just failed to reach statistical significance because of the small degrees of freedom and the rank-order shifts among formulations 1 to 5.
The linear correlations between cAMP levels and each individual marker of platelet function or integrity were less robust (not shown). Rather than presume a linear correlation between cAMP level and status of platelets during storage, we formulated an hypothesis that elevation of cAMP above some threshold level was sufficient to provide longterm preservation effects, and that further increases in cAMP above that threshold had a low impact on further improvements in storage of platelets. Examination of the minimum cAMP values among the concentrates in the three best formulations 
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gested that the cAMP thresholds were: greater than 22 at day IO, greater than 17 at day 15, and greater than 2 1 at day 20 between these groupings. In summary, it appeared that a sustained elevation of intracellular cAMP to levels greater than approximately 20 pmol/109 platelets was sufficient to provide adequate protection against deterioration of platelets caused by activation during storage in concentrates.
DISCUSSION
During storage in the blood bank, platelet concentrates gradually lose functionality and circulatory lifespan, leading to a state referred to as the platelet "storage lesion." The mechanisms involved in the deterioration of platelet concentrates have been debated for many years. One ofthe wellestablished hallmarks of the storage lesion has been a rapid acidification of the medium by cellular production of lactic acid; when the concentrate pH falls to 6.2 or less, platelet dysfunction is evident by most criteria. 24 The severity of this problem was somewhat ameliorated by the advent of plastic storage containers of high gas permeability, thus reducing hypoxia and lactate prod~ction.~~'~' The cause of high metabolic output by stored platelets remains unclear, although we have found that platelet-activation inhibitors reduce the metabolic rate of platelets in the new concentrate containe r~. '~ The early attempts to use prostaglandins to increase the yield of platelets during harvesting from donated blood did not appear to improve the quality of the stored platelet^."^ The tangible benefit seemed to be in easy resuspension of platelets and less loss in clumping after centrifugation of platelet-rich plasma to make a concentrate. Addition of acidic citrate solution on top of the pellet equally facilitated resuspension of platelets,28 so this effect would not seem to be specific to prostaglandins. The inhibition of platelet activation by close cell contact might explain the ease of resuspension imparted by prostaglandins or an acidic medium, but of more interest, the onset of the storage lesion was not abated by PGE-I or PGI-2. This observation might be taken as a repudiation of the hypothesis that platelet activation during concentrate preparation contributes to the deterioration of platelet function. However, the effect of inhibitory prostaglandins such as PGE-1 or PGI-2 is known to be transient and reversible,".'2 and there are several lines of evidence that platelet-activation agonists are generated continuously in platelet concentrates; by-products of activation appear throughout the storage Therefore, we assumed that to adequately limit platelet activation and its sequelae during storage of platelets, a more long-lasting effect was needed.
The data presented in this report show a strong correlation between sustained cAMP levels of greater than 20 pmol/ IO9 platelets and the improved preservation of platelets in concentrates. PGE-l alone or forskolin did not give a prolonged measurable rise in CAMP. Effective concentrations of phosphodiesterase inhibitors, especially when combined with PGE-I , gave appreciable and stable elevations in CAMP levels and significant improvements in platelet metabolism/integrity/function markers. TxB2 levels also reflected the benefit of phosphodiesterase inhibitors. The added benefit of a thrombin inhibitor (Thromstop; AmeriFor personal use only. on August 16, 2017 . by guest www.bloodjournal.org From 
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The lowest (best) ranks were accorded to the concentrates with the highest cAMP levels and the lowest TxB, levels. Abbreviation: NS, not significant.
can Diagnostics, New York, NY) and a general protease inhibitor (aprotinin) as shown in our other workI5 suggest that elevated cAMP does not prevent all mechanisms of damage to platelets during storage. The ability of strong platelet agonists like thrombin to overwhelm the effects of prostaglandins has been shown.30 From our present findings, we conclude that the earlier work with prostaglandins in platelet concentrates failed to show an expected improvement over controls because PGE-l (and PGI-2) cannot provide a sustained cAMP increase during a prolonged storage period.
Pharmacologic supplementation of platelet concentrates may improve quality and/or extend the shelf life of platelets in blood banking. The issues of maintaining sterility for extended periods of storage at 22°C and minimizing the potential toxicity of supplemented platelet concentrates remain to be addressed. Our results suggest that a high concentration ofa relatively nontoxic phosphodiesterase inhibitor such as theophylline or caffeine alone may be the simplest effective approach to investigate. Other formulations of inhibitors, including PGE-l and protease antagonists, may give slightly better results in certain in vitro markers, but the cost and probable toxicity risks mitigate against their potential use. In vivo platelet-survival studies may show that theophylline or caffeine provide a significant benefit equal to that which we already reported for the combination of theophylline and PGE-1 .21 Successful and practical inhibition of the activation-dependent storage lesion could greatly facilitate the management of platelet-concentrate inventories in blood banking and potentially improve the quality of care in transfusion medicine.
